The FDA Reauthorization Act would reinstate the agency’s user fee program through 2022. The current program, which is set to expire Sept. 30, allows the FDA to collect fees from drug or devicemakers for new product applications. The agency uses these funds — expected to total nearly $9 million by 2022 — to hire more staff and accelerate its product approval processes.
The House unanimously passed the bill last month. It now goes to the president for final approval.
More articles on supply chain:
6 must-reads for supply chain leaders this week
Express Scripts adds 64 drugs to exclusion list
10 most-read supply chain stories in July
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
